Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Sep;40(3):273–276. doi: 10.1111/j.1365-2125.1995.tb05784.x

Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.

W Cawello 1, A Leonhardt 1, H Schweer 1, H W Seyberth 1, R Bonn 1, A L Lomeli 1
PMCID: PMC1365109  PMID: 8527291

Abstract

Prostaglandin E1 (PGE1) (30, 60, 120 micrograms) was administered by intravenous infusion over a 120 min period in an open, three way randomized, cross-over study to 12 healthy male volunteers. For the evaluation of PGE1, PGE0 and 15-keto-PGE0, blood samples were drawn prior to, during and after the infusion. Analytical measurements were performed by gas chromatography/negative ion chemical ionization triple stage quadruple mass spectrometry, a highly specific and sensitive GC/MS/MS-method. During intravenous infusion of 30, 60 and 120 micrograms PGE1, endogenous plasma PGE1 concentrations increased from 1.7 +/- 0.8 to 4.2 +/- 1.1, 6.7 +/- 1.0 and 11.0 +/- 1.9 pg ml-1 respectively. PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively. Within the dose range of 30-120 micrograms PGE1 2 h-1 there was a linear increase of Cmax and AUC with the dose. The results of the analysis of variance after baseline and dose-correction show a 90% confidence interval in the bioequivalence acceptance range of 80 to 125%.

Full text

PDF
273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cawello W., Schweer H., Müller R., Bonn R., Seyberth H. W. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. Eur J Clin Pharmacol. 1994;46(3):275–277. doi: 10.1007/BF00192562. [DOI] [PubMed] [Google Scholar]
  2. Habon I., Fritsch S., Szejtli J. Simulation of pharmacokinetic behaviour of drug-cyclodextrin complexes. Pharmazie. 1984 Dec;39(12):830–834. [PubMed] [Google Scholar]
  3. Hamberg M., Samuelsson B. On the metabolism of prostaglandins E 1 and E 2 in man. J Biol Chem. 1971 Nov 25;246(22):6713–6721. [PubMed] [Google Scholar]
  4. Hirai M., Nakayama R. Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease. Br J Surg. 1986 Jan;73(1):20–23. doi: 10.1002/bjs.1800730109. [DOI] [PubMed] [Google Scholar]
  5. Kloeze J. Relationship between chemical structure and platelet-aggregation activity of prostaglandins. Biochim Biophys Acta. 1969 Oct 28;187(3):285–292. doi: 10.1016/0005-2760(69)90001-0. [DOI] [PubMed] [Google Scholar]
  6. Olsson A. G., Carlson L. A. Clinical, hemodynamic and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Res. 1976;1:429–432. [PubMed] [Google Scholar]
  7. Peskar B. A., Cawello W., Rogatti W., Rudofsky G. On the metabolism of prostaglandin E1 administered intravenously to human volunteers. J Physiol Pharmacol. 1991 Sep;42(3):327–331. [PubMed] [Google Scholar]
  8. Samuelsson B., Gréen K. Endogenous levels of 15-keto-dihydro-prostaglandins in human plasma. Parameters for monitoring prostaglandin synthesis. Biochem Med. 1974 Nov;11(3):298–303. doi: 10.1016/0006-2944(74)90127-6. [DOI] [PubMed] [Google Scholar]
  9. Schweer H., Meese C. O., Watzer B., Seyberth H. W. Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry. Biol Mass Spectrom. 1994 Mar;23(3):165–170. doi: 10.1002/bms.1200230308. [DOI] [PubMed] [Google Scholar]
  10. Trübestein G., von Bary S., Breddin K., Diehm C., Gruss J. D., Heinrich H., Horsch S., Kriessmann A., Maass U., Martin M. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study. Vasa Suppl. 1989;28:44–49. [PubMed] [Google Scholar]
  11. Uekama K., Hirayama F., Ikeda K., Inaba K. Utilization of cyclodextrin complexation for separation of E, A, and B prostaglandins by ion-exchange liquid chromatography. J Pharm Sci. 1977 May;66(5):706–710. doi: 10.1002/jps.2600660525. [DOI] [PubMed] [Google Scholar]
  12. Whittle B. J., Moncada S., Vane J. R. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978 Sep;16(3):373–388. doi: 10.1016/0090-6980(78)90216-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES